Wait For Me: AstraZeneca’s Durvalumab Gets Its Turn At The FDA

The FDA has accepted for review AstraZeneca’s anti-PD-L1 product durvalumab in bladder cancer and granted it a priority review, setting the stage for its market debut in the second quarter of 2017. But as the fifth PD1/L1 targeting product to market it will need to attract attention to itself.